Study of mutations in the mmpR and atpE genes associated with the development of Mycobacterium tuberculosis resistance to bedaquiline
https://doi.org/10.54921/2413-0346-2024-12-1-4-8
Abstract
In the study we obtained and analyzed the results of the development of resistance of Mycobacterium tuberculosis to the novel antitubercular drug bedaquiline. We investigate 16 strains isolated from 16 patients with pulmonary TB after bedaquiline therapy. With the help of wholegenome sequencing we detected 20 mutations in the mmpR gene and 6 mutations in the target gene atpE associated with bedaquiline resistance in vitro. It was found, that MIC values of bedaquiline were significantly higher for strains with mutations in the atpE gene than for MTB strains with mutations in the mmpR gene.
About the Authors
I. V. Peretokina
Federal State Budgetary Scientific Institution «Central Scientific Research Institute of Tuberculosis»
Russian Federation
Russian Federation
Moscow
L. Yu. Krylova
Federal State Budgetary Scientific Institution «Central Scientific Research Institute of Tuberculosis»
Russian Federation
Russian Federation
Moscow
G. E. Freiman
Federal State Budgetary Scientific Institution «Central Scientific Research Institute of Tuberculosis»
Russian Federation
Russian Federation
Moscow
E. Yu. Nosova
Federal State Budgetary Scientific Institution «Central Scientific Research Institute of Tuberculosis»
Russian Federation
Russian Federation
Moscow
D. V. Zimenkov
Engelhardt Institute of Molecular Biology (EIMB)
Russian Federation
Russian Federation
References
1. Васильева И.А., Тестов В.В., Стерликов С.А. Эпидемическая ситуация по туберкулезу в годы пандемии COVID-19 – 2020–2021 гг. // Туберкулез и болезни легких. – 2022. – Т. 100. – № 3. – С. 6-12.
2. Туберкулез у взрослых: клинические рекомендации. 2022–2023–2024 / Утв. Минздравом России от 04.03.2022. – [Электронный ресурс] http://disuria.ru/_ld/11/1173_kr22A15A19MZ.pdf.
3. Литвинов В.И., Макарова М.В., Носова Е.Ю., Сафонова С.Г. Изучение лекарственной чувствительности микобактерий туберкулеза // Туберкулез и социально значимые заболевания. – 2016. – №4. – С. 45-55.
4. Andries K., Villellas C., Coeck N., Thys K., Gevers T., Vranckx L., Lounis N., de Jong B.C., Koul A. Acquired resistance of Mycobacterium tuberculosis to bedaquiline // PLoS One. – 2014. – Vol. 9, № 7. – P. e102135.
5. Clinical and Laboratory Standards Institute (CLSI). Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes / CLSI document M24-A2. Аpproved standard. – 2nd ed. - Wayne, PA, 2011. – 61 р.
6. Nieto Ramirez L.M., Quintero Vargas K., Diaz G. Whole genome sequencing for the analysis of drug resistant strains of Mycobacterium tuberculosis: a systematic review for bedaquiline and delamanid // Antibiotics (Basel). – 2020. – Vol. 9, № 3. – P. 133.
7. Rodrigues C., Jani J., Shenai S., Thakkar P., Siddiqi S., Mehta A. Drug susceptibility testing of Mycobacterium tuberculosis against second-lane drugs using the Bactec MGIT 960 system // Int. J. Tuberc. Lung Dis. – 2008. – Vol. 12, № 12. – P. 1449-1455.
8. Rüsch-Gerdes S., Pfyffer G.E., Casal M., Chadwick M., Siddiqi S. Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials // J. Clin. Microbiol. – 2006. – Vol. 44, № 3. – P. 688-692.
9. Siddiqi S.H., Rusch-Gerdes S. MGIT procedure manual for BACTEC™ MGIT 960™ system. – Foundation for Innovative New Diagnostics, 2006. – 74 p. [Электронный ресурс] https://www.finddx.org/wp-content/uploads/2016/02/mgit_manual_nov2006.pdf.
10. Torrea G., Coeck N., Desmaretz C., Parre T.V.D., Poucke T.V., Lounis N., de Jong B.C., Rigouts L. Bedaquiline susceptibility testing of Mycobacterium tuberculosis in an automated liquid culture system // J. Antimicrob. Chemother. – 2015. – Vol. 70, № 8. – P. 2300-2305.
11. Zimenkov D.V., Nosova E.Y., Kulagina E.V., Antonova O.V., Arslanbaeva L.R., Isakova A.I., Krylova L.Y., Peretokina I.V., Makarova M.V., Safonova S.G., Borisov S.E., Gryadunov D.A. Examination of bedaquiline – and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region // J. Antimicrobial. Chemotherapy. – 2017. – Vol. 72, № 7. – P. 1901-1906.
12. World Health Organization. WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-resistant tuberculosis treatment. – Geneva: WHO, 2020. [Электронный ресурс] https://www.who.int/publications-detail-redirect/9789240007048.
Review
For citations:
Peretokina I.V., Krylova L.Yu., Freiman G.E., Nosova E.Yu., Zimenkov D.V. Study of mutations in the mmpR and atpE genes associated with the development of Mycobacterium tuberculosis resistance to bedaquiline. Tuberculosis and socially significant diseases. 2024;12(1):4-8. (In Russ.) https://doi.org/10.54921/2413-0346-2024-12-1-4-8
Views:
178
Email this article 